CL2014000224A1 - Compuestos derivados de heterociclos sustituidos, moduladores del transporte nuclear; composicion farmaceutica; y su uso para el tratamiento de un trastorno asociado con actividad crm1, tal como cancer, trastorno de crecimiento tisular anormal, fibrosis, entre otras. - Google Patents
Compuestos derivados de heterociclos sustituidos, moduladores del transporte nuclear; composicion farmaceutica; y su uso para el tratamiento de un trastorno asociado con actividad crm1, tal como cancer, trastorno de crecimiento tisular anormal, fibrosis, entre otras.Info
- Publication number
- CL2014000224A1 CL2014000224A1 CL2014000224A CL2014000224A CL2014000224A1 CL 2014000224 A1 CL2014000224 A1 CL 2014000224A1 CL 2014000224 A CL2014000224 A CL 2014000224A CL 2014000224 A CL2014000224 A CL 2014000224A CL 2014000224 A1 CL2014000224 A1 CL 2014000224A1
- Authority
- CL
- Chile
- Prior art keywords
- disorder
- fibrosis
- modulators
- cancer
- treatment
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 101150094313 XPO1 gene Proteins 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 208000037824 growth disorder Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 230000025308 nuclear transport Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000008467 tissue growth Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/50—Photovoltaic [PV] energy
- Y02E10/549—Organic PV cells
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513428P | 2011-07-29 | 2011-07-29 | |
| US201161513432P | 2011-07-29 | 2011-07-29 | |
| US201261653588P | 2012-05-31 | 2012-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000224A1 true CL2014000224A1 (es) | 2014-12-05 |
Family
ID=46682903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000224A CL2014000224A1 (es) | 2011-07-29 | 2014-01-29 | Compuestos derivados de heterociclos sustituidos, moduladores del transporte nuclear; composicion farmaceutica; y su uso para el tratamiento de un trastorno asociado con actividad crm1, tal como cancer, trastorno de crecimiento tisular anormal, fibrosis, entre otras. |
| CL2015001259A CL2015001259A1 (es) | 2011-07-29 | 2015-05-11 | Compuestos heterociclicos modulares del transporte nuclear; composicion farmaceutica; y usos de los mismos en enfermedades tales como cancer (div. sol. 224-14). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001259A CL2015001259A1 (es) | 2011-07-29 | 2015-05-11 | Compuestos heterociclicos modulares del transporte nuclear; composicion farmaceutica; y usos de los mismos en enfermedades tales como cancer (div. sol. 224-14). |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9428490B2 (enExample) |
| EP (1) | EP2736883B1 (enExample) |
| JP (3) | JP6006794B2 (enExample) |
| KR (1) | KR102022715B1 (enExample) |
| CN (1) | CN103842340B (enExample) |
| AU (2) | AU2016213805A1 (enExample) |
| BR (1) | BR112014001933A2 (enExample) |
| CA (1) | CA2842364A1 (enExample) |
| CL (2) | CL2014000224A1 (enExample) |
| EA (1) | EA201490406A1 (enExample) |
| MX (1) | MX350442B (enExample) |
| PE (1) | PE20141003A1 (enExample) |
| SG (1) | SG10201609097PA (enExample) |
| UA (1) | UA117902C2 (enExample) |
| WO (1) | WO2013019561A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011109799A1 (en) | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| JP6106605B2 (ja) | 2011-01-17 | 2017-04-05 | カリオファーム セラピューティクス，インコーポレイテッド | オレフィン含有核輸送調節剤およびその使用 |
| EP2736883B1 (en) * | 2011-07-29 | 2019-09-04 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| JP6005740B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | ヒドラジド含有核輸送調節因子およびその使用 |
| AU2013259384B2 (en) | 2012-05-09 | 2016-06-02 | Biogen Ma Inc. | Nuclear transport modulators and uses thereof |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| EP2968278B8 (en) * | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| WO2014205389A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2014205393A1 (en) * | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| BR112016000779A8 (pt) | 2013-07-18 | 2020-01-07 | Novartis Ag | inibidores de autotaxina que compreendem núcleo do ciclo de benzilamida de anel heteroaromático, seus usos, composição e combinação farmacêuticas |
| US9469650B2 (en) | 2013-11-08 | 2016-10-18 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide B derivatives |
| US9487536B2 (en) | 2013-11-08 | 2016-11-08 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide B derivatives |
| JP6527149B2 (ja) * | 2013-11-28 | 2019-06-05 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ベータ−サラセミアの処置のための方法及び医薬組成物 |
| US9745292B2 (en) | 2014-03-13 | 2017-08-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| EP3116501A1 (en) | 2014-03-13 | 2017-01-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2015196071A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| MX388170B (es) | 2014-08-15 | 2025-03-19 | Karyopharm Therapeutics Inc | Polimorfos de selinexor |
| US9981990B2 (en) | 2014-12-03 | 2018-05-29 | Bioventures, Llc | Melampomagnolide B dimers |
| CA2971835A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| EP3325474A1 (en) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| ES2930848T3 (es) | 2015-09-23 | 2022-12-22 | Xwpharma Ltd | Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos |
| KR20250136942A (ko) | 2015-10-06 | 2025-09-16 | 프로테오스타시스 테라퓨틱스, 인크. | Cftr 조절용 화합물, 조성물, 및 방법 |
| CN105384673B (zh) * | 2015-11-09 | 2017-11-14 | 南京富润凯德生物医药有限公司 | 3‑氟代‑氮杂环丁烷衍生物的合成方法 |
| MA43529A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| JP2019509980A (ja) * | 2016-01-29 | 2019-04-11 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | メランポマグノリドｂのトリアゾール誘導体及びその使用方法 |
| MA43775A (fr) | 2016-04-07 | 2021-05-05 | Proteostasis Therapeutics Inc | Analogues du ivacaftor conentant des atomes de silicium |
| WO2017212423A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemcical compounds |
| EP3472156B1 (en) | 2016-06-21 | 2023-06-07 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| EP3512515A1 (en) | 2016-09-16 | 2019-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
| WO2018098472A1 (en) | 2016-11-28 | 2018-05-31 | Karyopharm Therapeutics Inc. | Crm1 inhibitors for treating epilepsy |
| CN106831731B (zh) * | 2017-01-17 | 2019-11-08 | 广州市闻皓生物科技有限公司 | 一种Selinexor原料药的合成方法 |
| CN115025086A (zh) | 2017-03-30 | 2022-09-09 | 凯瑞康宁生物工程（武汉）有限公司 | 双环杂芳基衍生物及其制备与用途 |
| CA3087912C (en) | 2018-01-10 | 2023-03-14 | Xw Laboratories Inc. | Prodrugs of ketamine, compositions and uses thereof |
| WO2019232724A1 (en) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| CN110592141B (zh) * | 2018-06-13 | 2023-07-07 | 中国科学院上海有机化学研究所 | 用于调控基因编辑效率的化合物及其应用 |
| CN114042070A (zh) | 2018-09-30 | 2022-02-15 | 凯瑞康宁生物工程（武汉）有限公司 | 作为神经元组胺受体-3拮抗剂的化合物及其用途 |
| CN111606890A (zh) * | 2019-02-26 | 2020-09-01 | 微境生物医药科技(上海)有限公司 | 含丙烯酰基的核转运调节剂及其用途 |
| JP2020141256A (ja) | 2019-02-28 | 2020-09-03 | ソニーセミコンダクタソリューションズ株式会社 | 復調回路、復調方法、送信装置 |
| KR20220004142A (ko) | 2019-05-01 | 2022-01-11 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법 |
| TWI899126B (zh) | 2019-12-20 | 2025-10-01 | 香港商凱瑞康寧有限公司 | ４－纈胺醯氧基丁酸的合成方法 |
| WO2021257832A1 (en) | 2020-06-18 | 2021-12-23 | XWPharma Ltd. | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients |
| KR20230011359A (ko) | 2020-06-18 | 2023-01-20 | 엑스더블유파마 리미티드 | 수용성 활성 약제 성분의 제어 방출 과립화물 |
| WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
| WO2022076466A1 (en) | 2020-10-05 | 2022-04-14 | XWPharma Ltd. | Modified release compositions of a gamma-hydroxybutyric acid derivative |
| WO2022143779A1 (zh) * | 2020-12-29 | 2022-07-07 | 南京明德新药研发有限公司 | 含烯基类化合物及其应用 |
| EP4588471A3 (en) | 2021-03-19 | 2025-09-24 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative |
| JP7737544B2 (ja) | 2021-08-13 | 2025-09-10 | エックスダブリューファーマ リミテッド | ケタミン誘導体の医薬組成物及び経口剤形 |
| WO2024175804A1 (en) * | 2023-02-24 | 2024-08-29 | Katholieke Universiteit Leuven | Nuclear transport modulators |
| CN116514773B (zh) * | 2023-04-24 | 2024-12-03 | 重庆汉佩生物科技有限公司 | 一种Verdinexor(KPT-335)及其盐酸盐的合成方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR840000529A (ko) * | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| IL97249A (en) * | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| JP3111321B2 (ja) * | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| US5541213A (en) * | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5468353A (en) * | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
| JP2941950B2 (ja) * | 1994-11-23 | 1999-08-30 | ニューロゲン コーポレイション | 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド |
| US20030018025A1 (en) * | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| CA2229617A1 (en) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| CN1088711C (zh) * | 1996-04-04 | 2002-08-07 | 盐野义制药株式会社 | 头孢烯化合物及含该化合物的医药 |
| CN101817784B (zh) | 1996-04-25 | 2012-02-01 | 日产化学工业株式会社 | 乙烯衍生物和含有该衍生物的杀有害生物剂 |
| US5994398A (en) * | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) * | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| WO1999050264A1 (en) * | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Quinazoline derivatives |
| AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| CA2423868C (en) * | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| AU2002327627B2 (en) * | 2001-09-14 | 2006-09-14 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2004037248A2 (en) * | 2002-10-24 | 2004-05-06 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| CA2504511A1 (en) | 2002-11-01 | 2004-05-13 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| JP4145230B2 (ja) * | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| AU2003291403A1 (en) * | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| CA2512886A1 (en) * | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| BRPI0511504A (pt) * | 2004-05-26 | 2008-01-22 | Eisai R&D Man Co Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides |
| KR20070050475A (ko) * | 2004-08-11 | 2007-05-15 | 교린 세이야꾸 가부시키 가이샤 | 신규 환상 아미노 안식향산 유도체 |
| US20100130737A1 (en) * | 2005-02-18 | 2010-05-27 | Takeda Pharmaceutical Company Limited | Regulating Agent of GPR34 Receptor Function |
| AR057891A1 (es) | 2005-11-15 | 2007-12-26 | Otsuka Pharma Co Ltd | Compuestos de oxazol y composicion farmaceutica |
| EA016464B1 (ru) | 2006-03-09 | 2012-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Полициклические производные арилимидазола |
| CN101466670B (zh) * | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| DK2014652T3 (da) | 2006-04-18 | 2014-10-13 | Nippon Chemiphar Co | Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor |
| KR101130380B1 (ko) | 2006-06-13 | 2012-04-23 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도 |
| AU2007277519B2 (en) * | 2006-07-27 | 2011-12-22 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| EP2090570B1 (en) * | 2006-09-05 | 2011-11-09 | Kyowa Hakko Kirin Co., Ltd. | Imidazole derivative |
| EP1942104A1 (en) * | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| WO2011109799A1 (en) | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| JP6106605B2 (ja) | 2011-01-17 | 2017-04-05 | カリオファーム セラピューティクス，インコーポレイテッド | オレフィン含有核輸送調節剤およびその使用 |
| US9152882B2 (en) * | 2011-06-17 | 2015-10-06 | Microsoft Technology Licensing, Llc. | Location-aided recognition |
| EP2736883B1 (en) * | 2011-07-29 | 2019-09-04 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| JP6005740B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | ヒドラジド含有核輸送調節因子およびその使用 |
| AU2013259384B2 (en) | 2012-05-09 | 2016-06-02 | Biogen Ma Inc. | Nuclear transport modulators and uses thereof |
| US20160016916A1 (en) | 2013-03-15 | 2016-01-21 | Karyopharm Therapeutics Inc. | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2014205389A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
-
2012
- 2012-07-26 EP EP12748083.8A patent/EP2736883B1/en active Active
- 2012-07-26 JP JP2014523015A patent/JP6006794B2/ja active Active
- 2012-07-26 EA EA201490406A patent/EA201490406A1/ru unknown
- 2012-07-26 CN CN201280047930.1A patent/CN103842340B/zh active Active
- 2012-07-26 MX MX2014001180A patent/MX350442B/es active IP Right Grant
- 2012-07-26 UA UAA201401884A patent/UA117902C2/uk unknown
- 2012-07-26 US US14/235,342 patent/US9428490B2/en active Active
- 2012-07-26 CA CA2842364A patent/CA2842364A1/en not_active Abandoned
- 2012-07-26 KR KR1020147005649A patent/KR102022715B1/ko active Active
- 2012-07-26 WO PCT/US2012/048368 patent/WO2013019561A1/en not_active Ceased
- 2012-07-26 PE PE2014000137A patent/PE20141003A1/es active IP Right Grant
- 2012-07-26 BR BR112014001933A patent/BR112014001933A2/pt not_active Application Discontinuation
- 2012-07-26 SG SG10201609097PA patent/SG10201609097PA/en unknown
-
2014
- 2014-01-29 CL CL2014000224A patent/CL2014000224A1/es unknown
-
2015
- 2015-05-11 CL CL2015001259A patent/CL2015001259A1/es unknown
-
2016
- 2016-07-22 US US15/217,514 patent/US20170137430A1/en not_active Abandoned
- 2016-08-11 AU AU2016213805A patent/AU2016213805A1/en not_active Abandoned
- 2016-09-09 JP JP2016176098A patent/JP2016199604A/ja not_active Withdrawn
-
2018
- 2018-01-18 JP JP2018006773A patent/JP6752235B2/ja active Active
- 2018-06-14 AU AU2018204256A patent/AU2018204256A1/en not_active Abandoned
-
2019
- 2019-04-25 US US16/394,986 patent/US20200087313A1/en not_active Abandoned
-
2021
- 2021-05-04 US US17/307,656 patent/US20220056038A1/en not_active Abandoned
-
2023
- 2023-12-01 US US18/526,900 patent/US20240376114A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000224A1 (es) | Compuestos derivados de heterociclos sustituidos, moduladores del transporte nuclear; composicion farmaceutica; y su uso para el tratamiento de un trastorno asociado con actividad crm1, tal como cancer, trastorno de crecimiento tisular anormal, fibrosis, entre otras. | |
| CL2014000566A1 (es) | Compuestos derivados de pirrolopirimidina y purina, y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento del crecimiento celular anormal, tal como cancer. | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| CL2014000225A1 (es) | Compuestos derivados de 1,2,4-triazol; composicion farmaceutica; procedimiento de preparacion de procursores de los mismos y el uso como moduladores del transporte nuclear en el tratamiento de enfermedades tales como cancer. | |
| CL2015001265A1 (es) | Compuestos derivados de 2-aminoquinazolina sustituidos; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7 y/o tlr8 tal como infecciones viricas. | |
| CL2015003491A1 (es) | Compuestos químicos. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2013001009A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer. | |
| EP3165227A4 (en) | Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria | |
| EP2665519A2 (en) | Radiation treatment delivery system with ring gantry | |
| GT201400164A (es) | Compuestos de imidazopirrolidinona | |
| CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| CL2013000352A1 (es) | Compuesto derivado de isoxazolina como agentes antiparasitarios; composicion farmaceutica o veterinaria que comprende el compuesto; uso del compuesto para preparar un medicamento. | |
| MX353024B (es) | Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia. | |
| CL2015001461A1 (es) | Una formulación estabilizada de pemetrexed. | |
| EP3060143A4 (en) | Maintenance of bronchial patency by local delivery of cytotoxic, cytostatic, or anti-neoplastic agent | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| CL2015001610A1 (es) | Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende. | |
| DOP2017000219A (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| CO6940372A2 (es) | Péptidos con actividad antimicrobiana, composiciones medicamentosas para el tratamiento y profilaxis de animales, composiciones para el tratamiento y profilaxis de plantas, usos de los denominados péptidos y usos del extracto de paenibacillus elgii ourofinensis | |
| UY34754A (es) | ?mezcla para mejora del crecimiento de las plantas?. |